Pharmaceutical innovation : incentives, competition, and cost-benefit analysis in international perspective
著者
書誌事項
Pharmaceutical innovation : incentives, competition, and cost-benefit analysis in international perspective
Cambridge University Press, 2007
大学図書館所蔵 全5件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references (p. 293-317) and index
内容説明・目次
内容説明
The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being introduced. For this reason in part, health care budgets throughout the world have increased dramatically, eliciting growing pressures for cost containment. This book explores four important issues in pharmaceutical innovations: (1) the industry structure of pharmaceutical innovation; (2) incentives for correcting market failures in allocating resources for research and development; (3) competition and marketing; and (4) public evaluation of the benefits and costs of innovation. The lessons are applicable to countries all over the world, at all levels of economic development. By discussing existing evidence this book proposes incentive arrangements to accomplish social objectives.
目次
- 1. Introduction Frank Sloan and Chee-Ruey Hsieh
- Part I. The Industry Structure of Pharmaceutical Innovation: 2. The pharmaceutical sector in health care Uwe Reinhardt
- 3. The economics of research and development in the pharmaceutical industry William Comanor
- Part II. Structuring Incentives for Research and Development: 4. Drugs for neglected diseases: new incentives for innovation Aidan Hollis
- 5. When patents fail: finding new drugs for the developing world Stephen M. Maurer
- 6. Implementing a public subsidy for vaccines Frank Sloan and Charles Eesley
- 7. Ensuring the future supply of vaccines: is a National Vaccine Authority the answer? Frank Lichtenberg
- Part III. Competition and Marketing: 8. Competition between generic and branded drugs Henry Grabowski
- 9. The United States' experience with direct-to-consumer advertising of prescription drugs: what have we learned? Ernst Berndt
- Part IV. Public Evaluation of the Benefits and Costs of Innovation: 10. Measures of costs and benefits for drugs in cost effectiveness analysis Mark Pauly
- 11. Using economic evaluation in reimbursement decisions for health technologies: lessons from international experience Michael Drummond
- 12. Pharmaceutical spending and health outcomes Pierre Cremieux, Denise Jarvinen, Genia Long and Phi Merrigan
- 13. Pharmaceutical innovation and health outcomes: empirical evidence from Taiwan Chee-Ruey Hsieh, Kuang-Ta Vance Lo, Yichen Hong and Ya-Chen Tina Shih
- 14. Conclusions and policy implications Frank A. Sloan and Chee-Ruey Hsieh.
「Nielsen BookData」 より